Exscientia - Model EXALT1 -Clinical Trial Drug

Pioneering work by our team has delivered a platform able to anticipate the effectiveness of cancer treatments in the clinic, using AI to analyse the activity of drugs in live patient samples, at single-cell resolution.

EXALT1 is the ?rst-ever prospective interventional study of its kind. Predictions made by the platform proposed which therapy would be most effective for late stage haematological cancer patients based on testing drug responses ex vivo in their own tissue samples.

EXALT-1 demonstrated real-world patient selection capabilities by achieving a 55% response rate and statistically significant improvement in progression free survival over the prior line of therapy for patients that were treated following the platform’s recommendation.

In a post hoc analysis, patients receiving therapy recommended by the platform showed significantly improved outcomes compared to their prior treatments, whereas patients who received treatments other than the platform recommended therapy showed worse outcomes.